RESEARCH-RELATED CONFLICTS OF INTEREST

SUMMARY STATEMENT

Research-related conflicts of interest (“COI”) occur when an institution or an individual, including his or her Family, enter into any type of relationship that interferes with or compromises, or gives the appearance of compromising, the professional judgment or Research obligations of the institution or individual. A Research-related COI also may arise if there is a Conflict of Commitment regarding outside activities that interfere with the primary Research obligation of the individual to his or her employer or Sponsor. Any research-related COI or potential COI must be fully disclosed, evaluated and, if necessary, managed, reduced or eliminated. The purpose of this policy is to describe the research conflicts of interest that may occur within Atrium Health and to set forth procedures for disclosure and management of these conflicts with adherence to applicable regulations, related guidelines and the policies and procedures of Atrium Health. This policy is in addition to, and not in lieu of, other Atrium Health conflicts of interest policies.

APPLICABILITY

The Research-Related Conflicts of Interest Policy applies to all Atrium Health teammates, students or trainees, in their performance of the administration, Research, teaching, patient care and other business operations of Atrium Health and to non-teammates who are appointed by Atrium Health to represent its interest on various committees or in other decision-making capacities. Covered Individuals and Investigators may be subject to different requirements, as set forth below.

The Research-related Conflicts of Interest Policy is applicable to all Atrium Research Projects, regardless of funding source.

DEFINITIONS

A) “Applicant” means the party who submits a marketing application to FDA for approval of a drug, device, or biologic product or who submits a reclassification petition.

B) “Awarding Component” means the organizational unit of either the Public Health Service or other sponsor that sponsors/funds a particular Research grant. The Awarding Component typically makes case-by-case determinations on steps to be taken to ensure that the design, conduct, and reporting of the Research will not be biased by any conflicting Financial Interest of a Covered Individual.

C) “Atrium Research Project” means any Research, testing, evaluation, training, and/or instruction project conducted under the auspices of Atrium Health.
D) “Compelling Circumstances” means those facts that convince the Research COI Committee or its
designee that a Covered Individual who has a Financial Interest should be permitted to conduct an
Atrium Research Project, taking into account the following factors:

(1) the nature of the Atrium Research Project,
(2) the magnitude of the Financial Interest and the degree to which it is related to the
Atrium Research Project,
(3) the extent to which the Financial Interest could be directly and substantially affected by
the Atrium Research Project,
(4) if the Atrium Research Project involves Human Subjects, the degree of risk to the
Human Subjects involved that is inherent in the Research protocol,
(5) the extent to which the Investigator is uniquely qualified to perform a Research study
with important public benefit, and
(6) the extent to which the Financial Interest is amenable to effective oversight and
management.

E) “Conflict of Commitment” means a situation in which outside activities interfere with the primary
obligations of the Covered Individual to Atrium Health. A Conflict of Commitment is a Conflict
of Interest for the purposes of this policy.

F) “Conflict of Interest” (COI) means a situation in which a Covered Individual, including his or her
Family, or Atrium Health enters into any type of relationship that interferes with or compromises,
or gives the appearance of compromising, the professional judgment or obligations of the Covered
Individual or Atrium Health. The term Conflict of Interest includes Conflicts of Commitment.

G) “Conflict of Interest Disclosure Form” means the form used by Atrium Health to obtain
information about relationships that may pose a potential conflict of interest as defined by this
policy. Such disclosures are in addition to any other conflicts disclosures required to be disclosed
under other conflicts of interest policies.

H) “Covered Clinical Study” means any study of a drug or device in humans submitted in a marketing
application or reclassification petition subject to this part that the Applicant or Food and Drug
Administration (FDA) relies on to establish that the product is effective or any study in which a
single Investigator makes a significant contribution to the demonstration of safety.

I) “Covered Individual” means any Atrium Health teammate, student or trainee who is performing
teaching, Research, public service, administration and/or business operations for Atrium Health.
This includes sub-recipient Investigator of PHS-funded Research and his/her Family.

J) “Disclosure” means an Investigator’s disclosure of Financial Interests to the Institution related to
his or her institutional responsibilities.

K) “Disclosable Financial Interest” (DFI) means financial interest consisting of one or more of the
following interests:

(1) Any compensation made to the Investigator by any sponsor of the Covered Clinical Study in
which the value or compensation could be affected by study outcome.
(2) A proprietary interest in the tested product including, but not limited to, a patent, trademark,
copyright or licensing agreement.
(3) Any equity in any sponsor of the Covered Clinical Study, i.e., any ownership interest, stock options, or other financial interest whose value cannot be readily determined through reference to public prices.

(4) Any equity interest in any sponsor of the covered study if the sponsor is a publicly held company and the interest exceeds $50,000 in value.

(5) Significant payments of other sorts (SPOOS) are payments that have a cumulative monetary value of $25,000 or more and are made by any sponsor of a clinical study to the Investigator or the Investigator’s Institution during the time the Investigator is carrying out the study and for one year following completion of the study. This would include payments that support activities of the Investigator (e.g., a grant to the Investigator or to the Institution to fund the Investigator’s ongoing Research or compensation in the form of equipment), exclusive of the costs of conducting the clinical study or other clinical studies, or to provide other reimbursements such as retainers for ongoing consultation or honoraria.

The requirement applies to the above interests held during the time the Investigator is carrying out the study and for one year following the completion of the study.

L) “Entity” means an organization other than the Institution, whether public or private. Examples include the following: companies, partnerships, professional associations, non-profits organizations, voluntary health organization, etc.

M) “Family” means any of the following in relation to a Covered Individual:

   (1) Spouse, as defined below.
   (2) Natural or adoptive parent, child or sibling.
   (3) Stepparent, stepchild, stepbrother, or stepsister.
   (4) Father-, mother-, daughter-, son-, brother, or sister-in-law.
   (5) Grandparent or grandchild.
   (6) Spouse of a grandparent or grandchild.

N) “Financial Interest” means anything of monetary value, including, but not limited to, salary or other payments for services, equity interests, and intellectual property rights, whether or not the value is readily ascertainable. Financial Interests include:

   (1) Receipts of rights or expectation to receive any income by the Covered Individual or his or her Family from a business whether in the form of a fee (e.g., consulting), salary, allowance, forbearance, forgiveness, dividend, royalty derived from licensing technology, rent, capital gain, real or personal property, or any other form of compensation;
   (2) Any stock, stock option, or similar equity interest in a business by a Covered Individual or his or her Family, excluding any interest that arises solely in a business through mutual, pension, or other institutional investment fund over which the Covered Individual or her or his Family does not exercise control; or
   (3) Gifts that have been made to Atrium Health for the benefit of the Research or other professional activities of a specific Covered Individual.

Financial Interest does not include salary or other remuneration from Atrium Health.
O) “Financial Conflict of Interest (FCOI)” means a Significant Financial Interest or Disclosable Financial Interest that could directly and significantly affect the design, conduct, or reporting of Research, regardless of funding source.

P) “Financially Interested Company” means an Entity with financial interests that would reasonably appear to be affected by the conduct or outcome of an Atrium Research Project. This term includes the manufacturer (including business partners) of the drug or the device or other Sponsor of an Atrium Research Project as well as any Entity acting as the agent of a Financially Interested Company, e.g., a contract research organization. (This term also includes companies that provide direct and primary competition for the investigational product, if the Covered Individual has actual knowledge that the financial interests of such a company would reasonably appear to be affected by the Atrium Research Project.)

Q) “Human Subject” means a living individual about whom an Investigator (whether professional or student) conducting Research obtains (1) data through intervention or interaction with the individual, or (2) identifiable private information.

R) “IACUC” means the Atrium Health Institutional Animal Care and Use Committee.

S) “Institution” means Atrium Health.

T) “Institutional Financial Interest” means one of the following circumstances:

(1) Royalties – When Atrium Health is entitled to receive royalties (payments linked to the sale of a product) that is or was under investigation at Atrium Health.

(2) Any Equity in a Non-Publicly Traded Sponsor – When, through Atrium Health’s technology licensing activities or investments related to such activities, Atrium Health has obtained an equity interest or an entitlement to equity of any value (including options or warrants) in a current non-publicly traded Sponsor of an Atrium Research Project.

(3) Equity Exceeding $100,000 in a Publicly-traded Sponsor – When, through Atrium Health’s technology licensing activities or investments related to such activities, Atrium Health has obtained an equity interest or an entitlement to equity of any value (including options or warrants) in a current publicly-traded Sponsor of an Atrium Research Project. (Exception: Mutual Funds and Fiduciary-Managed Funds – Interests of any amount in publicly-traded, diversified mutual funds or in funds in which the investment decision making is made by fiduciary managers appointed by Atrium Health but not otherwise affiliated with Atrium Health are not Institutional Financial Interests.)

- Managers – When a Manager (or his or her Family or a controlled Entity), whether participating in Research or not, holds a personal Financial Interest in any commercial research sponsor that is sponsoring an Atrium Research Project or a product being investigated for clinical use at or by Atrium Health, except that having equity or royalties up to $10,000 from a publicly-traded Sponsor is not an Institutional Financial Interest if the Manager is not participating in the Research.

U) “Institutional Responsibilities” means an Investigator’s professional responsibilities on behalf of the Institution, including, but not limited to, activities such as Research, Research consultation,
teaching, professional practice, patient care, institutional committee memberships, and service on panels.

V) “Investigator” means the project director or principal investigator and any other person, regardless of title or position and including collaborators or consultants, who is responsible for the design, conduct or reporting of a proposed or approved Atrium Research Project. All Investigators are Covered Individuals.

W) “IACUC” is the Atrium Health Institutional Animal Care and Use Committee.

X) “IRB” is the Atrium Health Institutional Review Board, inclusive of a designated external IRB contracted by Atrium to perform those services.

Y) “OGC” is the Atrium Health Office of General Counsel.

Z) “Participate(ing)” in an Atrium Research Project means a Covered Individual doing any of the following under the auspices of Atrium Health or pursuant to the review and approval of the IRB or IACUC, whether the Atrium Research Project is conducted at an Atrium Health-owned, leased or managed facility, in an Atrium Health hospital, or anywhere else in the world:

1) Designing or directing an Atrium Research Project;
2) Serving as the principal investigator, co-investigator, or sub-investigator;
3) Enrolling Research subjects (including obtaining Human Subjects’ informed consent, if applicable);
4) Making decisions related to eligibility to Research subjects’ enrollment in an Atrium Research Project;
5) Analyzing or reporting Atrium Research Project data, and/or
6) Submitting manuscripts concerning the Atrium Research Project for publication as a primary author or co-author.

AA) “PHS” is the Public Health Service, which is an agency of the U.S. Department of Health and Human Services (HHS) and any components of the PHS to which the authority involved may be delegated, including the National Institutes of Health (NIH).

BB) “Remuneration” means salary and any payment for services not otherwise identified as salary (e.g. consulting fees, honoraria, paid authorship); equity interest includes any stock, stock option or other ownership interest.

CC) “Research” means a systematic investigation, including Research development, testing and evaluation, designed to develop or contribute to generalizable knowledge.

DD) “Research COI Committee” means the committee responsible for review and assessment of real or potential Conflicts of Interest related to Atrium Research Projects. The Bylaws of the Research COI Committee are attached hereto as Appendix I.

EE) “Responsible Administrator” means the administrator or business unit leader who is responsible for a particular Covered Individual.
FF) “Senior/key personnel” means the project director/principal investigator and any other person identified as senior/key personnel by the institution in the grant application, progress report, or any other report submitted to the PHS.

GG) “Significant Financial Interest” (SFI) means financial interest consisting of one or more of the following interests of the Investigator and their Family that reasonably appears to be related to the Investigator’s Institution, including:
   (1) The value of Remuneration received from an Entity in the 12 months preceding the Disclosure and the value of any equity interest in the Entity as of the date of Disclosure, when aggregated exceeds $5,000.
   (2) Intellectual property rights and interests (e.g. patents, copyrights), upon receipt of income related to such rights and interests.
   (3) Reimbursement for sponsored travel related to the Covered Individual’s institutional responsibilities (i.e. that which is paid on behalf of the Investigator but not reimbursed to the Investigator so that the exact monetary value may not be readily available). This does not include travel reimbursed or sponsored by Federal, state or local government agencies, institutions of higher education, academic teaching hospital, a medical center, or a research institute that is affiliated with an institution of higher education.

HH) “Sponsor” of a Covered Clinical Study means a party financially supporting a study.

II) “Spouse” includes a person to whom a Covered Individual is married or with whom the Covered Individual lives together in the same residence, shares responsibility for each other’s welfare and shares financial obligations.

POLICIES AND PROCEDURES

I. Research-related Conflicts of Interest

A. Policy

Without the prior approval of the leader of Research Compliance and Conflicts, in consultation with Enterprise Research, a Covered Individual may not participate in any Atrium Research Project if the Covered Individual or his or her Family has a Significant Financial Interest (“SFI”) or Disclosable Financial Interest (“DFI”) related to the Covered Individual’s Institutional responsibilities.

Assessment
The leaders of Research Compliance and Conflicts as authorized by the Chief Compliance Officer, are the designated institutional officials responsible for soliciting and reviewing Disclosures of SFIs and DFIs of Covered Individuals participating in any Atrium Research Project. In consultation with Enterprise Research and Enterprise Compliance, the Research Compliance and Conflicts also must approve any Atrium Research Project in which Atrium has an Institutional Financial Interest in the sponsor of the Atrium Research Project or any other Financially Interested Company.

Compelling Circumstances
Research Compliance and Conflicts, in consultation with Enterprise Research and Enterprise Compliance, is responsible for determining whether Compelling Circumstances exist. If
Compelling Circumstances are found to exist, the Atrium Research Project may be conducted and/or the Covered Individual may participate in the Atrium Research Project. If such determination is made, a management plan documenting the Compelling Circumstances, approval by the Research COI Committee and, where applicable, ratification by the IACUC or IRB.

B. Procedure

1. Disclosure

   All Covered Individuals must complete a Conflict of Interest Disclosure Form at the time of hire and on an annual basis, which is reviewed and maintained by the Compliance Department. The Conflict of Interest Disclosure Form and information contained within shall be considered confidential and treated as such by the Compliance Department and only disclosed to those individuals with a need to know. Investigators are subject to additional disclosure requirements as set forth below.

   a. Investigators must disclose SFIs and DFIs at the time of application for any Atrium Research Project by updating the Conflict of Interest Disclosure Form. Any additional updates must be submitted within 30 days of discovering or acquiring a new SFI or DFI including, but not limited to, the consideration of a new Atrium Research Project which the Investigator believes may either:

      (1) Give rise to a Conflict of Interest, or
      (2) Eliminate a Conflict of Interest previously disclosed.

   b. Other situations requiring prior Disclosure by Investigators include, but are not limited to, the following:

      (1) Service as an officer or director of any Entity;
      (2) Investment of more than $5,000 in any one company whose product/service is related to an individual’s Research or work;
      (3) Equity interest of any value in a partnership or corporation;
      (4) Consulting contracts that yield more than $5,000 a year in remuneration;
      (5) Consulting contracts that require more than 26 days per year of outside commitment (more than ½ day per week per year);
      (6) Agreements to collaborate in Research with a commercial Entity, regardless of value;
      (7) With respect to Family members, situations 1 thru 6 must be resolved as an Investigator also must disclose members of his or her Family, if the Investigator is aware that a member of his or her Family had such a relationship;
      (8) Income related to intellectual property rights and interests, upon receipt of such income;

2. The occurrence of any reimbursed or sponsored travel (i.e. paid on behalf of the Investigator and not reimbursed to Investigator).

3. Covered Individuals will cooperate with any requests for additional information by the Compliance Department, Conflicts Office, or other interested parties.

Review

Printed copies of this document are considered an uncontrolled document. Refer to Atrium Health's PolicyTech system for the latest version.
The Atrium Health Compliance Office designee for Research Compliance will review each Conflict of Interest Disclosure Form that contains a potential SFI or DFI in consultation with other Atrium Health officials, as appropriate. As a result Research Compliance, in consultation with the Enterprise Research, Research Conflicts Office, and Enterprise Compliance, as necessary, may:

a. Take no action, if the Disclosure is not an SFI or DFI;
b. Determine a management plan acknowledging the presence of a FCOI exists and Atrium is aware of such FCOI, or
c. Refer the Disclosure to the Research COI Committee for further evaluation.

4. Research COI Committee

a. The composition and responsibilities of the Research COI Committee are set forth in the by-laws in Appendix I.
b. When Research Compliance, in consultation with the leadership of Research, Research Conflicts, and Enterprise Compliance as warranted, determine additional review of an FCOI is necessary, the Research COI Committee shall convene to review the FCOI and determine what, if any, steps shall be taken to mitigate the conflict.
c. In addition, the Research COI Committee will periodically evaluate the reports that it receives and develop a listing of (institutionally) Financially Interested Companies and provide that listing to the IRB, IACUC, OGC and other departments as necessary.

5. Reporting Requirements for PHS-funded Research

When a COI exists for a PHS funded project, the Institution will provide initial, annual, revised review reports to the Awarding Component within 60 days of identifying the COI. Additionally, as required by the IRB, the Form FDA 3455, Disclosure: Financial Interests and Arrangements of Clinical Investigators Statement must be completed for each Investigator who, or whose Family, has or had DFI and/or arrangements with any Sponsor of a Covered Clinical Study.

6. Management, Reduction and Elimination of Conflicts of Interest in Research

If it is determined that appropriate conditions, restrictions or both are necessary to manage, reduce or eliminate a Research-related Conflict of Interest, such conditions, restrictions or both will be imposed.

If, upon review of Disclosures of SFIs and DFIs, it is determined by Research Compliance and Conflicts that a management plan is necessary to manage a Financial Conflict of Interest (FCOI), such management plan will be implemented which specifically details the actions that have been, and will be, taken to manage such FCOI. In some instances, the management plan may simply acknowledge and document the FCOI and require no further action.

Examples of conditions or restrictions include, but are not limited to:

a. Public disclosure of the Financial Interests or Institutional Financial Interests;
b. Disclosure of Conflict of Interest to Research subjects;

c. Divestiture of Financial Interests or Institutional Financial Interests;

d. Monitoring of Atrium Research Project by independent reviewers;

e. Modification of the Research plan;

f. Disqualification from Participation by Covered Individual(s) in all or a portion of the Atrium Research Project;

g. Oversight by an independent teammate or outside party of roles that can affect collection of data and analysis of data; and,

h. Severance of relationships that create actual or potential Conflicts of Interest.

Management plans shall be drafted by Enterprise Compliance and sent to the Investigator and his/her Responsible Administrator or other supervisor for signature.

The Institution shall complete a good faith review of any Investigator’s activities and his or her Atrium Research Project if it is determined that a FCOI was mismanaged or not disclosed properly by the Investigator or Institution. This review will be conducted within 120 days of the determination of noncompliance. In instances where the Investigator’s failure to comply with this policy or any associated procedure or management plan, and the design, conduct, or reporting of an Atrium Research Project appears to have been biased, the Institution will immediately notify and submit a mitigation report to the Awarding Component detailing the corrective actions taken or planned to be taken by the institution.

The Institution is required to permit an onsite review of all records relating to compliance of any Investigator Disclosure of SFI or DFI by the applicable granting institution, HHS or the Awarding Component at any time before, during or after award.

7. **Retention**

All FCOI records, including Conflict of Interest Disclosure Forms, management plans and all other related documents, will be maintained for at least three (3) years from the date of submission of the final expenditures report.

8. **Subrecipient Requirements**

If an Atrium Research Project is carried out through a subrecipient, such subrecipient shall comply with this policy unless they are able to demonstrate that the subrecipient institution’s FCOI policy complies with, at a minimum, all applicable laws and regulations. The subrecipient’s requirements to comply with this policy or use the subrecipient institution’s FCOI policy shall be outlined in a written agreement between Atrium Health and the subrecipient site.

9. **Education Requirements**

All Covered Individuals participating in an Atrium Research Project will be informed of this policy and their responsibilities regarding Disclosure of SFI and DFI. Additionally, each Covered Individual will receive information about applicable regulations and will participate in training on this policy. Education and training will occur prior to beginning
any Atrium Research Project and thereafter by regulatory, Atrium and/or other requirements.

Prior to engaging in any Atrium Research Project, all Investigators and Research Staff must complete CITI Training Modules, as required by Atrium Health and by regulation. Investigators who are added to the Research Project after commencement will also complete the CITI Training Modules.

CITI Training must be repeated periodically as required by Atrium and applicable regulation immediately under the following circumstances:

- Policy revisions as to affect the Investigator’s current obligations,
- Or, if the Investigator has been found in violation of this policy or an applicable management plan set forth by the Institution.

10. Public Accessibility

This Research-Related COI Policy is accessible on the external Atrium Health website. If this policy is unavailable due to website maintenance, then the policy will be made available within five (5) business days of a request. The Institution will make available to the public upon request, information concerning any SFI or DFI disclosed to the Institution that meets the following three criteria:

- The SFI or DFI is held by the senior/key personnel of the active PHS projects;
- The Institution determines that the SFI or DFI is related to PHS funded Research;
- The Institution determines that the SFI or DFI is a FCOI.

The information request must be made to the Enterprise Compliance department who will respond within five (5) business days of receipt of the request. Disclosed information will be provided to the extent required by applicable PHS regulations and state law.

II. Compliance

All Covered Individuals are expected to comply fully and promptly with all requirements of this policy. Failure on the part of a Covered Individual to comply may result in disciplinary action and/or sanctions; examples of possible sanctions include formal reprimand; suspension and/or termination of Research privileges (i.e., clinical, basic science, comparative medicine); and/or any other enforcement action mandated by the applicable government granting agency or Atrium Health administration. The designated leaders from Enterprise Research, Research Compliance and Conflicts, in coordination with the Chief Compliance Officer are responsible for investigating instances of noncompliance and determining whether to impose sanctions and what sanctions will be applied. In making these determinations, they may consult with the Responsible Administrator, the Research COI Committee, OGC, human resources and/or other appropriate individuals. A Covered Individual who is the subject of a disciplinary action may appeal such action in accordance with established Atrium Health grievance and/or disciplinary procedures.

APPROVALS

Printed copies of this document are considered an uncontrolled document. Refer to Atrium Health’s PolicyTech system for the latest version.
<table>
<thead>
<tr>
<th>Policy Coordinator</th>
<th>Christine Becker, AVP Enterprise Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy Approver</td>
<td>Alicia Bowers, Senior Vice President, Chief Privacy and Compliance Officer</td>
</tr>
</tbody>
</table>

Printed copies of this document are considered an uncontrolled document. Refer to Atrium Health’s PolicyTech system for the latest version.
APPENDIX I
BYLAWS OF RESEARCH CONFLICT OF INTEREST (COI) COMMITTEE

The Research COI Committee will include the following members or their designees: Vice President Research (Chair), Chief Compliance Officer, Chair of IRB, a member of OGC, Assistant Vice President Research Compliance, and Experienced Researcher(s). The Research COI Committee will meet as needed as determined by the Chair or his or her designee. Meetings may only proceed with a quorum, which will consist of a simple majority. The Research COI Committee’s responsibilities are:

- Operate in accordance with the Standard Operating Procedure for the Disclosure and Management of Significant Financial Interest and Disclosable Financial Interest in Research;
- Recommend policies and procedures to address research-related Conflicts of Interest within Atrium Health;
- Review Conflict of Interest Disclosures Forms to determine if Investigators have Conflicts of Interest, Significant Financial Interests or Disclosable Financial Interests that might compromise, or appear to compromise, the protection of Human Subjects, the integrity of Atrium Research Projects, or otherwise inhibits objectivity in the conduct of an Atrium Research Project;
- Recommend if and how conflicts, SFIs or DFIs identified in the Conflict of Interest Disclosures Form and through further discussion with the Investigator should be managed, reduced, or eliminated through Conflict of Interest management plans; and
- Oversee/monitor Conflict of Interest management plans, with progress reports submitted as needed.

The Chair of the Research COI Committee will make certain that proper records are maintained, specifically:

- Minutes of each meeting with the names of those present
- The issues and Disclosures reviewed
- A summary of the discussion of the issues
- Other Research COI Committee actions and discussion

These records will be maintained in the Atrium Health Compliance Office for at least three (3) years after the termination or completion of the Atrium Research Project to which those records relate or until resolution of any government activity related to those records.